

1 **The aerobiology of SARS-CoV-2 in UK hospitals and the impact of aerosol generating**
2 **procedures**

3 Susan Gould^{1*}, Rachel L Byrne^{1*}, Thomas Edwards¹, Ghaith Aljayyousi¹, Dominic Wooding¹,
4 Kate Buist¹, Konstantina Kontogianni¹, Allan Bennett², Barry Atkinson², Ginny Moore², Jake
5 Dunning³, Stacy Todd⁴, Marie-Claire Hoyle⁴, Lance Turtle⁵, Tom Solomon^{4,5,6,7}, Richard
6 Fitzgerald⁵, Mike Beadsworth⁴, Paul Garner¹, Emily R Adams¹, and Tom Fletcher^{1,4}

7 ¹Liverpool School of Tropical Medicine, Liverpool, UK.

8 ²UK Health Security Agency

9 ³University of Oxford

10 ⁴Liverpool University Hospitals NHS Foundation Trust

11 ⁵University of Liverpool

12 ⁶National Institute for Health Research Health Protection Research Unit in Emerging and
13 Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, University of
14 Liverpool

15 ⁷The Walton Centre NHS Foundation Trust

16 *authors contributed equally

17 **Running title: SARS-CoV-2 aerosols in AGP rooms (max 50 characters)**

18 **Sources of funding:** SG, EA, JD, LT, TS and TF are supported by the National Institute for Health
19 Research (NIHR) Health Protection Research Unit in Emerging and Zoonotic Infections. SG and
20 PG are supported by the READ-It (project number 300342-104) which is funded by UK aid from
21 the UK government. PhD stipend from the medical research council to RLB.

22 **Conflicts of Interest:** Emily Adams is Director of Epidemics and NTDs at Global Access diagnostics.

23 **Corresponding author:** Rachel L Byrne, Liverpool School of Tropical Medicine, Pembroke Place,
24 Liverpool UK. E-mail: Rachel.byrne@lstm.ac.uk phone number: 01517053100

25 **Keywords:** COVID-19, aerobiology, Aerosol generating procedure

26 **Word count:** Abstract, 250; Manuscript, 3047

27 **Authors' contributions:** The study was conceived by ERA, RLB, TF and SG. The study design was
28 developed by ERA, BA, AB, RLB, TE, TF, SG and GM. Data collection and extraction was
29 conducted by RLB, SG, MH. Laboratory work was completed by KB, RLB, SG, KK and DW. Data
30 analysis and interpretation were conducted by GA, BA, MB, AB, RLB, JD, TE, RF, TF, PG, SG, GM,
31 TS, ST, LT and DW. The initial manuscript was prepared by GA, RLB and SG. All authors edited
32 and approved the final manuscript.

33 **Abstract (250 words)**

34 Background

35 SARS-CoV-2 nosocomial transmission to patients and healthcare workers (HCWs) has occurred
36 throughout the COVID-19 pandemic. Aerosol generating procedures (AGPs) seemed particularly
37 risky, and policies have restricted their use in all settings. We examined the prevalence of
38 aerosolized SARS-CoV-2 in the rooms of COVID-19 patients requiring AGP or supplemental
39 oxygen compared to those on room air.

40 Methods

41 Samples were collected prospectively near to adults hospitalised with COVID-19 at two tertiary
42 care hospitals in the UK from November 2020 – October 2021. The Sartorius MD8 AirPort air
43 sampler was used to collect air samples at a minimum distance of 1.5 meters from patients. RT-
44 qPCR was used following overnight incubation of membranes in culture media and extraction.

45 Results

46 We collected 219 samples from patients' rooms: individuals on room air (n=67) , receiving
47 oxygen (n=65) or AGP (n=67). Of these, 54 (24.6%) samples were positive for SARS-CoV-2 viral
48 RNA. The highest prevalence was identified in the air around patients receiving oxygen (32.3%,
49 n=21, CI95% 22.2 to 44.3%) with AGP and room air recording prevalence of (20.7%, n=18,
50 CI95% 14.1 – 33.7%) and (22.3%, n=15, CI95% 13.5 – 30.4%) respectively. We did not detect a
51 significant difference in the observed frequency of viral RNA between interventions.

52 Interpretation

53 SARS-CoV-2 viral RNA was detected in the air of hospital rooms of COVID-19 patients, and AGPs
54 did not appear to impact the likelihood of viral RNA. Enhanced respiratory protection and
55 appropriate infection prevention and control measures are required to be fully and carefully
56 implemented for all COVID-19 patients to reduce risk of aerosol transmission.

57 **Background**

58 Since the emergence of the severe acute respiratory syndrome coronavirus (SARS-CoV-2) in
59 2019 there have been intense efforts to understand the natural history of COVID-19 disease
60 and transmission characteristics. The risk of nosocomial transmission has been well reported
61 and personal protective equipment (PPE) requirements for healthcare workers (HCWs) has
62 generated significant discussion internationally¹. The World Health Organization (WHO)
63 recently estimated that between 80 000 and 180 000 HCWs have died of COVID-19 up to May
64 2021².

65 Aerosol generating procedures (AGPs) such as non-invasive ventilation (NIV) have been
66 considered essential in providing respiratory support for patients with severe COVID-19 and in
67 reducing the need for invasive ventilation which is associated with higher morbidity and
68 mortality, others such as High Flow oxygen have now been shown to offer no benefit in
69 comparison with conventional oxygen³⁻⁵. Despite improved patient outcomes, AGPs came
70 under increased scrutiny during the severe acute respiratory syndrome (SARS) outbreak of
71 2003, when observational data suggested AGPs increased the risk of healthcare workers (HCW)
72 acquiring infection⁶. Hesitancy in adopting NIV, high flow oxygen or performing other AGPs may
73 be attributable to perceived risk to HCWs or limited availability of resources thought to be pre-
74 requisite such as negative pressure ventilation and higher-grade PPE⁷. In addition, there is a
75 lack of consensus as to what classes as an AGP and international guidelines (such as WHO, the
76 Centers for Disease Control (CDC) or UK Health Security Agency (UK HSA)) are based on expert
77 opinion due to a lack of solid evidence base.

78 Air sampling studies in healthcare settings have reported a broad range of frequencies of
79 detection of SARS-CoV-2. Multi-centre environmental sampling performed by UK HSA in 2020
80 in 8 UK hospitals identified SARS-CoV-2 RNA in 4 of 55 air samples collected <1m from patients⁸.
81 Other studies have reported rates of 0-72%^{9,10} PCR positivity in air samples. More recent
82 environmental sampling within the RECOVERY-RS (Randomised Evaluation of COVID-19
83 Therapy, Respiratory Support) study included air samples collected during administration of
84 continuous positive airways pressure (CPAP), high flow nasal oxygen (HFNO) and supplemental

85 oxygen. Of 90 air samples from 30 patients 14% were positive for at least one target on PCR and
86 no statistical difference in frequency of positivity was identified between the three groups
87 (CPAP, HFNO and other oxygen)¹¹. In healthy volunteers, two studies have demonstrated that
88 coughing, speaking or heavy breathing generate significantly higher volumes of detectable
89 respiratory particles than use of CPAP or HFNO^{12,13}.

90 However, confirmation of the significance of SARS-CoV-2 in the air in hospitalised settings has
91 not been definitive due to the absence of routine air sampling in a prospective COVID-19
92 patient cohort, with the WHO calling for further studies on the risk of SARS-CoV-2 release
93 during AGPs⁷. A range of approaches have been adopted to investigate the relative risk of
94 aerosol transmission in comparison to other modes like fomite, direct contact or close-range
95 droplet¹⁴. Further, there is a recognized need to identify which precautions would be most
96 effective in mitigating risks, to better protect communities and healthcare services including
97 vulnerable patients and staff.

98 This study addresses the question of whether there is an increased likelihood of detecting
99 aerosolized SARS-CoV-2 RNA in the rooms of COVID-19 patients undergoing AGPs than in the
100 rooms of patients requiring oxygen at flow rates of less than 15L/min via mask or nasal
101 cannulae, or not requiring any supplemental oxygen. For the purposes of this study, AGPs are
102 defined as those listed by UKHSA for which specific guidance on infection prevention and
103 control (IPC) measures is provided in the UK (UKHSA 2022)¹⁵ (Figure 1).

104 **Figure 1: List of procedures defined as aerosol generating procedures (UKHSA)**

- 105 • *Tracheal intubation and extubation
- 106 • Manual ventilation
- 107 • Tracheotomy or tracheostomy procedures (insertion or removal)
- 108 • *Bronchoscopy
- 109 • Dental procedures (using high speed devices, for example ultrasonic scalers/high speed drills)
- 110 • *Non-invasive ventilation (NIV); bi-level positive airway pressure ventilation (BiPAP) and continuous
111 positive airway pressure ventilation (CPAP)
- 112 • *High flow nasal oxygen (HFNO)
- 113 • High frequency oscillatory ventilation (HFOV)
- 114 • Induction of sputum using nebulised saline
- 115 • Respiratory tract suctioning
- 116 • Upper ear, nose, and throat (ENT) airway procedures that involve respiratory suctioning

- 117 • *Upper gastro-intestinal endoscopy where open suction of the upper respiratory tract occurs beyond the
- 118 oro-pharynx
- 119 • High speed cutting in surgery/post-mortem procedures if respiratory tract/paranasal sinuses involved

120 *indicates procedures included in this study

121 **Methods (781)**

122 **Setting**

123 Liverpool University Hospitals NHS Foundation Trust have two acute tertiary referral hospital
124 sites within Liverpool, UK (Royal Liverpool University (RLUH) and Aintree University Hospitals
125 (AUH)) that have each managed large cohorts of COVID-19 patients. CPAP, non-invasive
126 ventilation and use of high-flow oxygen were rapidly adopted as therapeutic interventions in
127 Liverpool¹⁶ but are listed as AGPs. AGPs were conducted in areas with enhanced ventilation,
128 including pre-existing negative pressure rooms, newly installed temporary systems providing
129 ventilation or areas such as theatre or intensive care. Together with UK-HSA, who had already
130 undertaken air and environmental sampling in hospitals⁸ we continued to collect air samples
131 from the rooms of patients hospitalised with COVID-19.

132 Prospective air sampling was performed around inpatients with a recent diagnosis of SARS CoV-
133 2 and in community ambulatory cases (n=13) admitted to the clinical research unit for
134 screening or treatment as part of an early phase trial. Samples included in this interim analysis
135 were collected between November 2020 and October 2021, and the dominant circulating
136 variants in the UK during this period were B.1.1.7 Alpha (PANGO lineage B.1.1.7) and Delta
137 (PANGO lineage B.1.617.2)¹⁷. Locations sampled include high dependency units, NIV units,
138 critical care units, infectious diseases, respiratory and general wards, and emergency departments.
139 No additional biological samples or clinical information were collected from the patients whose
140 rooms was sampled. No changes to behaviour or clinical care were requested from staff or
141 patients during sampling periods, staff and patients were aware that sampling was taking place.
142 Samples were categorised as either 1) room samples; patients not undergoing any respiratory
143 treatment 2) oxygen; patients undergoing oxygen at flow rates of less than 15L/min via nasal
144 cannulae/mask or 3) AGP; patients undergoing an AGP.

145 **Sample collection and processing**

146 To collect air samples, we used the Sartorius MD8 AirPort portable air sampler with gelatin
147 membranes (Sartorius, Germany). To ensure aerosols were captured and to minimize the
148 collection of large droplets, the sampler was placed at approximately 1.5 meters¹⁸ and the
149 sampler faced away from the participant. When sampling at a participant's bedside, the
150 sampler was typically placed on a hospital chair or table. At each sampling timepoint 1000L of
151 air was collected at a flow rate of 40 L/min.

152 Once completed the gelatin membrane was removed from the sampler using clean gloves, and
153 placed in a sterile 50ml Falcon tube (Corning Science, United States). Samples were transported
154 to the Biological Safety level 3 (BSL3) laboratories at the Liverpool School of Tropical Medicine
155 within 2 hours of sample collection. The gelatin membranes were immediately suspended in
156 10ml Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine solution (FBS; both
157 ThermoFisher, USA) and 50 units per ml of penicillin/streptomycin (Gibco, US). Samples were
158 vortexed and then stored overnight at 4°C to allow the membrane to fully dissolve without
159 impacting the stability of SARS-CoV-2¹⁹.

160 **RNA extraction, PCR and cell culture**

161 Following overnight storage, samples were brought to room temperature by incubation for up
162 to two hours. 140µl (1.4%) of each sample was then taken for RNA extraction. Viral RNA was
163 extracted using the QIAamp viral RNA mini kit (Qiagen, Germany) following the manufacturer's
164 instructions with an internal RT-qPCR extraction control incorporated before the lysis stage
165 (ThermoFisher, USA). Once extracted samples were taken immediately for downstream
166 application and stored at 4°C during PCR setup.

167 For SARS-CoV-2 RT-qPCR detection, 10µl of extracted RNA was tested using the TaqPath™
168 COVID-19 CE-IVD RT-PCR assay (ThermoFisher, USA) that detects three different SARS-CoV-2
169 genomic regions (ORF1ab, N gene, S gene), on the QuantStudio 5 platform (ThermoFisher,
170 USA). The PCR was deemed to be positive if one SARS-CoV-2 target and the internal control
171 amplified, this differs from the manufacturer instructions whereby two SARS-CoV-2 targets

172 must amplify however this is for clinical samples rather than for environmental samples. We do
173 not infer viability of the viral RNA we detected and thus the presence/absence of viral RNA is
174 recorded here. In instances of low Ct values the third target can often be out competed and
175 thus viral load calculations have not been appropriate using this assay. Samples were negative if
176 only the internal extraction control amplified.

177 Cell culture was attempted using a methodology adapted from Edwards *et al*²⁰. For samples
178 identified as the Alpha variant, based on S gene deletion, a 5-day incubation post inoculation
179 was used due to the variant's slower growth rate and smaller plaque sizes in Vero E6 cells²¹.
180 For all other samples a 3-day post inoculation incubation was utilized, as is routine laboratory
181 procedure. After three passage events, samples were fixed with 10% formalin, stained using
182 crystal violet and visually inspected for viral plaques.

183 **Statistical Analysis**

184 All data handling and manipulation was performed through R 3.6.3²². Binomial generalized
185 linear models (GLM) were performed to assess the ability of procedure to detect a positive
186 result, with time since infection, cycle threshold (Ct) value and location of patient included as
187 co-variates. Chi-Square test was performed to estimate the effect of procedure on detecting a
188 positive result in isolation from other factors. Additionally one-way ANOVA tests were
189 performed to assess quantitative differences between Ct values among different methods for
190 each gene.

191 **Ethics and Approvals**

192 This study was performed in conjunction with UK HSA as part of the COVID-19 clinical response.
193 In line with UK Health Resource Authority guidance this was performed as a service evaluation
194 and consisted of environmental sampling and simplified and anonymized routinely collected
195 patient information. The environmental sampling process was explained to patients and verbal
196 consent obtained.

197 **Results (450)**

198 A total of 219 air samples were collected during this study from bed spaces of 199 individuals
 199 (with some patient sampled at more than one timepoint) either on room air only (n=67),
 200 receiving supplemental oxygen (n=65) or undergoing an AGP (n=87) (Table 1).

201 **Table 1: Procedures sampled, and frequency of positive results observed**

Aerosol generating procedures		Non-aerosol generating procedures	
Procedure	percent positive (n/N)	Procedure	percent positive (n/N)
CPAP hood or mask	19.2% (10/52)	Room air	24.6% (17/69)
BiPAP	0% (0/3)	Oxygen - Nasal cannulae	28.6% (8/28)
Hi Flow oxygen (mask or nasal)	14.3% (3/21)	Oxygen – Venturi mask	33.3% (9/27)
Intubation	100.0% (1/1)	Oxygen – NRB	20.0% (1/5)
Bronchoscopy	100.0% (2/2)	Other/Not known	75% (3/4)
Endoscopy	50.0% (1/2)		
All	20.9% (17/81)		28.6% (38/133)

202 CPAP Continuous positive airway pressure. BiPAP Bilevel Positive Airway Pressure.
 203 NRB Non-rebreathe.
 204


205 The median number of days since onset of symptoms was 7 (Table 2). In total, 24.7% (n=55,
 206 CI95% 19.4-30.8%) were positive for SAR-CoV-2 viral RNA (Appendix 1). The highest prevalence
 207 was identified in the air around patients who were receiving oxygen (32.3%, n=21, CI95% 22.2
 208 to 44.3%) with AGP and room air recording prevalence of 20.7% (n=18, CI95% 14.1 – 33.7%) and
 209 22.3% (n=15, CI95% 13.5 – 30.4%) respectively, as shown in figure 2. The likelihood of a sample
 210 being PCR positive was not influenced by procedure (GLM, p >0.05).

211 **Table 2: Number of days between onset of symptoms and sample collection within each group**

	AGP	Oxygen	Room air	All
Median number of days since onset of symptoms	10 (1-27)	7 (0-42)	5 (1-12)	7(0-42)
Onset of symptoms unknown	5	2	1	8
Asymptomatic	2	1	17	20


212 AGP Aerosol generating procedure.

213 We did not detect a difference in Ct values for positive samples between procedure ($p > 0.05$,
214 one-way ANOVA), shown in figure 3. We observed a reduced detection of S gene, indicative of
215 Alpha variant presence, compared to other RT-qPCR genomic targets (ORF1 and N gene). Mean
216 Ct values for AGPs, Oxygen and Room air were 32.18, 33.08 and 33.88 respectively and cell
217 culture for each sample was negative.



218

219 **Figure 2: The percentage of samples PCR positive for SARS-CoV-2 viral RNA collected from the rooms of PCR**
220 **positive patients in two Liverpool Hospitals.** There was no statistically significant difference between aerosol
221 generating procedures (AGP), oxygen or room air and the likelihood of detecting viral RNA (GLM, $p > 0.05$). N.s.
222 indicates no statistical difference between the three methods (one-way ANOVA, $p > 0.05$).



223

224 **Figure 3: The cycle threshold (Ct) value of SARS-CoV-2 positive samples for each procedure (aerosol generating**
225 **procedure and oxygen) and room air.** The PCR used utilize three distinct regions of the SARS-CoV-2 genome
226 (ORF1, Nucleocapsid (N) gene and spike (S) gene). It is important to note that the alpha variant has significant
227 mutations in the s gene is not detectable, resulting in fewer data points. N.s. indicates no statistical difference
228 between the three methods for each gene (one-way ANOVA, $p > 0.05$).

229 We did not detect an effect of the number of days since reported onset of symptoms and the
230 frequency of detection of viral RNA or Ct values (GLM, $P > 0.05$). Further, no association
231 between RT-qPCR results and sampling location e.g., emergency department or critical care unit
232 was identified (GLM, $p > 0.05$). Of note, there was no obvious difference in positive results for

233 the Oxygen or Room air groups when sampling in standard ventilation areas rather than
234 enhanced ventilation areas (RR in Oxygen group 1.22, RR in Room Air group 1.08) (Table 3).

235 **Table 3: Type of ventilation, estimated air changes (ACH) and frequency of observed positive PCR results in each**
236 **group**

Type of ventilation	Estimated air changes	Intervention		
		Oxygen	AGP	Room air only
Neutral pressure	6	9/25	0/0	8/39
Negative Pressure	12	10/34	15/66	4/21
Unknown		2/6	0/3	0/2
ITU/Theatre	10	0/0	3/12	0/0

237 ITU Intensive Therapy Unit, AGP Aerosol generating procedure

238 An additional 16 air samples were taken in areas either occupied or used by patients with
239 confirmed SARS-CoV-2 infection (e.g. bathroom, nursing station), or directly adjacent i.e.
240 considered to be at risk of contamination (appendix 1), SARS-CoV-2 RNA was detected in 5 of
241 these. Culture was negative, and fungal overgrowth was noted in the bathroom samples. Of 4
242 samples collected in shared patient bathrooms 2 were RNA positive, as were 2 of 8 collected at
243 nursing stations, the remaining positive sample was collected in an ITU bay. Five of the nursing
244 station samples were from stations within 'red' zones, 1 from an area adjacent to a red zone,
245 and 2 from ward nursing stations more than 3 metres from COVID-19 patient rooms with
246 separating doors. The Ct values of these 5 samples ranged from 22.4 (S gene) at a nursing
247 station where sample was positive for all 3 genes tested, to 35.19 (for only one gene) for the
248 second positive nursing station sample and patient bathrooms. The positive sample collected in
249 a COVID-19 bay (with the nearest patient intubated) was positive for N gene and ORF1 genes.

250 Discussion

251 The factors that facilitate nosocomial transmission of SARS-CoV-2 remain incompletely
252 understood, including any additional risks posed by AGPs. To improve understanding and
253 inform IPC recommendations we have undertaken the largest air sampling study for SARS-Cov-2
254 published to date. In this report we provide evidence for the presence of SARS-CoV-2 viral RNA
255 isolated from the air of clinical environments in UK hospitals. In line with previous reports^{23,24},
256 we found Ct values to be high (typically above 30), indicative of low viral loads present. We did

257 not record any significant difference in the observed frequency of viral RNA detection nor viral
258 load between different procedures being undertaken including AGPs. Interestingly, we did
259 observe higher positivity rates in individuals receiving oxygen (flow rates of less than 15L/min
260 via nasal cannulae) than either AGP patients or those without supplementary oxygen although
261 not statistically significant.

262 The viral dynamics of SARS-CoV-2 in human disease is now well reported with higher viral loads
263 and transmission risk predominantly occurring earlier in disease course. Commonly used AGPs
264 such as CPAP are usually required later in the clinical course with median time from onset of
265 symptoms to development of respiratory failure being 8-12 days²⁸. However, we did not see a
266 significant relationship between time since symptom onset and likelihood of viral RNA
267 detection. Infective SARS-CoV-2 virus is rarely identified from clinical samples beyond 9 days
268 from onset of symptoms²⁶ and thereby chances of capturing viable virus may be confounded.
269 We were unable to culture samples, likely due to the high Ct values observed, dilutional effect
270 and due to the challenges in culturing virus after potential desiccation during the methods of air
271 sampling. Two reports describe the isolation of infectious SARS-CoV-2 from air sampling.
272 Lednicky *et al* describe isolation of SARS-CoV-2 virus from hospital rooms used by 2 patients
273 and a vehicle occupied by an infected individual with sequencing of cultured virus matching
274 that of the cases sampled^{27,28}. Another challenge in isolating virus from air samples was
275 identified by Lednicky *et al* as another respiratory virus was found to potentially overgrow
276 SARS-CoV-2 in culture²⁷. Santarpia *et al* described cytopathic effect (CPE), suggested increase in
277 RNA titre on days 3 and 4 of culture and presence of viral proteins on immunofluorescent
278 staining in 1 air sample but could not confirm cultivation of virus²⁴. Published aerobiology
279 studies in healthcare settings use a wide array of methods such as filtering air through gelatin,
280 PTFE or PC membranes, using liquid cyclonic sampling such as the Coriolis (Bertin), or impaction
281 e.g., Anderson samplers (Appendix 2). Sampling distances from specified patients sampled
282 varied from 10cm to 3m. Lednicky *et al* utilised a water condensation collection method (VIVAS)
283 and Santarpia the Sartorius MD8 airport sampler with gelatin membrane filters^{24,27}. The
284 diversity of study design and equipment as well as processing and analytical methods presents
285 challenges in comparing the results of different studies. Less than 10 air sampling studies

286 identified through literature search have reported attempted cell culture^{10,11,27,29-31}, and the
287 majority have been unable to confirm presence of viable virus despite detection of SARS CoV-2
288 RNA through PCR^{11,29,31}. This is likely attributable to the insensitivity of cell culture, which
289 requires a large inoculum and represents an imperfect model of infection of the human
290 nasopharynx. These challenges are increased when considering environmental samples with
291 low concentrations of detectable viral RNA and the degree of dilution involved in air sampling
292 methods including our own.

293 It is now accepted that a spectrum of expelled sizes of respiratory particles exist with risk of
294 infection dependent on additional key factors. These include variables relating to the person
295 (e.g., symptoms, duration of illness, individual variation in respiratory particle dispersion) and
296 those related to place (e.g., ventilation, proximity to susceptible individuals) that may be
297 equally or more important than the procedures undertaken. As this was a pragmatic
298 environmental sampling study, detailed patient level data and correlation with clinical SARS
299 CoV-2 samples was not available. This is a recognized limitation as individual characteristics and
300 the viral load detectable on clinical samples may impact likelihood of detection of viral RNA or
301 viable virus in the environment. AGPs were conducted in negative pressure single rooms, pods
302 or bays and bronchoscopy or endoscopy in designated facilities in accordance with Health
303 Technical memorandum 03-01 (including minimum 10 air changes per hour). Those on room air
304 or oxygen were more commonly cared for in rooms with neutral pressure. We also recognise
305 that multiple factors affect the potential impact of infective aerosols including temperature,
306 humidity and ventilation, patient and staff behaviour and pre-existing natural or vaccine
307 mediated immunity.

308 This study adds to the data of air sampling studies conducted within hospitals caring for COVID-
309 19 patients and offers reassurances to HCW performing AGPs that the presence of SARS-CoV-2
310 in the air is no different compared with environments where no AGPs are taking place. Our data
311 supports the conclusions drawn from the recent exploratory air sampling study conducted on
312 30 participants within the RECOVERY RS trial in which CPAP, HFNO and supplementary oxygen


313 via venturi were compared. The observed frequency of detection was not significantly higher in
314 the AGP groups¹¹.

315 Internationally differing lists of AGPs have been produced e.g. including or excluding nebulized
316 therapies or cardiopulmonary resuscitation. In the UK the expert panel responsible for
317 formulating such a list assessed the available evidence as ‘poor quality’¹⁵. AGPs vary widely and
318 more sampling around a broader range of procedures is required to establish whether there is
319 any evidence of increased risk associated. Any reduction in protections for potentially
320 vulnerable staff or patients regarding AGPs would require more certainty which could only be
321 provided by a more comprehensive evidence base. As we move towards endemicity of COVID-
322 19, it remains imperative to protect HCW and vulnerable patients from nosocomial infections.
323 Appropriate PPE and mask use are essential as SARS-CoV-2 is frequently detectable in the air
324 surrounding positive patients. We believe our data supports the use of FFP2/3 medical masks
325 for HCWs caring for COVID-19 patients, particularly for those with prolonged contact in line
326 with HSE guidelines¹⁵. As we move forwards, we must continue to avoid oversimplifying the
327 transmission dynamics of SARS-CoV-2 including into ‘droplet vs aerosol’, as this can lead to
328 fixed IPC recommendations and must now appreciate that the ‘person, place and procedure’
329 influence transmission risk. Future recommendations must be guided by emerging evidence
330 including ongoing studies to identify transmission differences that may occur with new variants
331 of concern.

332 **Role of the funding source**

333 The study funders had no influence over the design, conduct, analysis and interpretation of the
334 study; nor the writing of the report and the decision to submit the paper for publication.

335 **References**

- 336 1 Thomas JP, Srinivasan A, Wickramarachchi CS, Dhesi PK, Hung YMA, Kamath A V.
337 Evaluating the national PPE guidance for NHS healthcare workers during the COVID-19
338 pandemic. *Clin Med J R Coll Physicians London* 2020; **20**: 242–7.
- 339 2 World Health Organisation. Health and Care Worker Deaths during COVID-19. 2021.
340 [https://www.who.int/news/item/20-10-2021-health-and-care-worker-deaths-during-](https://www.who.int/news/item/20-10-2021-health-and-care-worker-deaths-during-covid-19)
341 covid-19 (accessed Oct 21, 2021).
- 342 3 Wozniak DR, Rubino A, Tan AL, *et al.* Positive role of continuous positive airway pressure
343 for intensive care unit patients with severe hypoxaemic respiratory failure due to COVID-
344 19 pneumonia: A single centre experience. *J Intensive Care Soc* 2022; **23**: 27–33.
- 345 4 Ashish A, Unsworth A, Martindale J, *et al.* CPAP management of COVID-19 respiratory
346 failure: A first quantitative analysis from an inpatient service evaluation. *BMJ Open Respir*
347 *Res* 2020; **7**: e000692.
- 348 5 Perkins GD, Ji C, Connolly BA, *et al.* Effect of Noninvasive Respiratory Strategies on
349 Intubation or Mortality among Patients with Acute Hypoxemic Respiratory Failure and
350 COVID-19: The RECOVERY-RS Randomized Clinical Trial. *JAMA - J Am Med Assoc* 2022;
351 **327**: 546–58.
- 352 6 Judson SD, Munster VJ. Nosocomial transmission of emerging viruses via aerosol-
353 generating medical procedures. *Viruses*. 2019; **11**. DOI:10.3390/v11100940.
- 354 7 Diaz, Janet; Appiah, John; Askie, Lisa; Baller, April; Banerjee, Anshu; Barkley, Shannon;
355 Bertagnolio, Silvia; Hemmingsen, Bianca; Bonet, Mercedes; Cunningham J. COVID-19: 
356 Clinical management Living guidance. 2021
357 <https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1> (accessed
358 Sept 6, 2021).
- 359 8 Moore G, Rickard H, Stevenson D, *et al.* Detection of SARS-CoV-2 within the healthcare

- 360 environment: a multi-centre study conducted during the first wave of the COVID-19
361 outbreak in England. *J Hosp Infect* 2021; **108**: 189–96.
- 362 9 Li YH, Fan YZ, Jiang L, Wang HB. Aerosol and environmental surface monitoring for SARS-
363 CoV-2 RNA in a designated hospital for severe COVID-19 patients. *Epidemiol Infect* 2020.
364 DOI:10.1017/S0950268820001570.
- 365 10 Ang AXY, Luhung I, Ahidjo BA, *et al.* Airborne SARS-CoV-2 surveillance in hospital
366 environment using high-flowrate air samplers and its comparison to surface sampling.
367 *Indoor Air* 2021; : 1–10.
- 368 11 Winslow RL, Zhou J, Windle EF, *et al.* SARS-CoV-2 environmental contamination from
369 hospitalised patients with COVID-19 receiving aerosol-generating procedures. *Thorax*
370 2021; : thoraxjnl-2021-218035.
- 371 12 Wilson NM, Marks GB, Eckhardt A, *et al.* The effect of respiratory activity, non-invasive
372 respiratory support and facemasks on aerosol generation and its relevance to COVID-19.
373 *Anaesthesia* 2021; **76**: 1465–74.
- 374 13 Hamilton FW, Gregson F, Arnold DT, *et al.* Aerosol emission from the respiratory tract: an
375 analysis of relative risks from oxygen delivery systems. *medRxiv* 2021; :
376 2021.01.29.21250552.
- 377 14 Nissen K, Krambrich J, Akaberi D, *et al.* Long-distance airborne dispersal of SARS-CoV-2 in
378 COVID-19 wards. *Sci Rep* 2020; **10**: 1–9.
- 379 15 UKHSA. Infection prevention and control for seasonal respiratory infections in health and
380 care settings (including SARS-CoV-2) for winter 2021 to 2022. Updated 17 January 2022.
381 2022. [https://www.gov.uk/government/publications/wuhan-novel-coronavirus-](https://www.gov.uk/government/publications/wuhan-novel-coronavirus-infection-prevention-and-control/covid-19-guidance-for-maintaining-services-within-health-and-care-settings-infection-prevention-and-control-recommendations#transmission-based-precautions)
382 [infection-prevention-and-control/covid-19-guidance-for-maintaining-services-within-](https://www.gov.uk/government/publications/wuhan-novel-coronavirus-infection-prevention-and-control/covid-19-guidance-for-maintaining-services-within-health-and-care-settings-infection-prevention-and-control-recommendations#transmission-based-precautions)
383 [health-and-care-settings-infection-prevention-and-control-](https://www.gov.uk/government/publications/wuhan-novel-coronavirus-infection-prevention-and-control/covid-19-guidance-for-maintaining-services-within-health-and-care-settings-infection-prevention-and-control-recommendations#transmission-based-precautions)
384 [recommendations#transmission-based-precautions.](https://www.gov.uk/government/publications/wuhan-novel-coronavirus-infection-prevention-and-control/covid-19-guidance-for-maintaining-services-within-health-and-care-settings-infection-prevention-and-control-recommendations#transmission-based-precautions)

- 385 16 Nightingale R, Nwosu N, Kutubudin F, *et al.* Is continuous positive airway pressure (CPAP)
386 a new standard of care for type 1 respiratory failure in COVID-19 patients? A
387 retrospective observational study of a dedicated COVID-19 CPAP service. *BMJ Open*
388 *Respir Res* 2020; **7**: 8–10.
- 389 17 Hadfield J, Megill C, Bell SM, *et al.* NextStrain: Real-time tracking of pathogen evolution.
390 *Bioinformatics* 2018; **34**: 4121–3.
- 391 18 World Health Organization. Modes of transmission of virus causing COVID-19:
392 implications for IPC precaution recommendations. *Geneva World Heal Organ* 2020; : 19–
393 21.
- 394 19 Chin AWH, Chu JTS, Perera MRA, *et al.* Stability of SARS-CoV-2 in different environmental
395 conditions. *The Lancet Microbe* 2020; **1**: e10.
- 396 20 Edwards T, Kay GA, Aljanyoussi G, *et al.* SARS-CoV-2 Transmission Risk from sports
397 Equipment (STRIKE). *medRxiv* 2021; : 2021.02.04.21251127.
- 398 21 Jeong GU, Yoon GY, Moon HW, *et al.* Comparison of plaque size, thermal stability, and
399 replication rate among SARS-CoV-2 variants of concern. *Viruses* 2022; **14**: 4–8.
- 400 22 R Core Team. R: A language and environment for ## statistical computing. 2017.
- 401 23 Chia PY, Coleman KK, Tan YK, *et al.* Detection of air and surface contamination by SARS-
402 CoV-2 in hospital rooms of infected patients. *Nat Commun* 2020; **11**.
403 DOI:10.1038/s41467-020-16670-2.
- 404 24 Santarpia JL, Rivera DN, Herrera VL, *et al.* Aerosol and surface contamination of SARS-
405 CoV-2 observed in quarantine and isolation care. *Sci Rep* 2020; **10**. DOI:10.1038/s41598-
406 020-69286-3.
- 407 25 Li X, Ma X. Acute respiratory failure in COVID-19: Is it ‘typical’ ARDS? *Crit Care* 2020; **24**:
408 1–5.

- 409 26 Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of
410 SARS-CoV-2. *BMJ* 2020; **371**: 1–6.
- 411 27 Lednicky JA, Lauzard M, Fan ZH, *et al.* Viable SARS-CoV-2 in the air of a hospital room
412 with COVID-19 patients. *Int J Infect Dis* 2020; **100**: 476–82.
- 413 28 Lednicky JA, Lauzardo M, Alam MM, *et al.* Isolation of SARS-CoV-2 from the air in a car
414 driven by a COVID patient with mild illness. *Int J Infect Dis* 2021; **108**: 212–6.
- 415 29 Zhou J, Otter JA, Price JR, *et al.* Investigating Severe Acute Respiratory Syndrome
416 Coronavirus 2 (SARS-CoV-2) Surface and Air Contamination in an Acute Healthcare
417 Setting During the Peak of the Coronavirus Disease 2019 (COVID-19) Pandemic in
418 London. *Clin Infect Dis* 2021; **73**: e1870–7.
- 419 30 Binder RA, Alarja NA, Robie ER *et al.* Environmental and aerosolized severe acute
420 respiratory syndrome coronavirus 2 among hospitalized coronavirus disease 2019
421 patients. *J Infect Dis* 2020; **222**: 1798–806.
- 422 31 Dumont-Leblond N, Veillette M, Mubareka S, *et al.* Low incidence of airborne SARS-CoV-
423 2 in acute care hospital rooms with optimized ventilation. *Emerg Microbes Infect* 2020; **9**:
424 2597–605.
- 425
- 426

427 **Research in Context**

428 **Evidence before this study**

429 We searched Pubmed (Medline, Web of science (Science citation index-Expanded and Biosis)
430 and Embase for air sampling studies published between January 2020 and November 2021.
431 Selected search terms were “COVID-19”, “SARS-Cov-2”, “air sampler”, “indoor air quality”,
432 “bioaerosol” and “indoor airborne” with 326 results. Studies in which healthcare environments
433 occupied by SARS-CoV-2 infected humans were sampled were eligible. After screening of
434 abstracts and then full texts 37 papers were included.

435 Frequency of detection of viral RNA in air samples collected from COVID-19 patients varied
436 widely from 0% to 100% and factors affecting likelihood of positivity were not consistently
437 identified. Whilst isolation of infectious virus from air samples is not always attempted, it has
438 only been reported twice but this reflect the challenges of fragile virus capture. Laboratory
439 studies have demonstrated that SARS-CoV-2 may persist for several hours in airborne particles,
440 and epidemiological research has illustrated probable airborne transmission of COVID-19 in
441 settings such as restaurants. Observational data from the SARS-CoV-1 epidemic suggested that
442 aerosol generating procedures (AGPs) presented a greater transmission hazard than other care,
443 that required enhanced respiratory protection. Winslow et al recently reported that in a cohort
444 of 30 patients, that AGPs were not associated with increased likelihood of SARS-CoV-2 viral RNA
445 detection in air compared to supplemental oxygen use. Studies of aerosol generation from
446 procedures such as CPAP and high flow oxygen on healthy volunteers in controlled
447 environments had predicted a low risk of airborne transmission related to such procedures in
448 comparison to cough, speech or singing.

449 **Added value of this study**

450 As the largest study to date to investigate SARS CoV-2 RNA detection in air samples from rooms
451 of patients undergoing different interventions including AGPS this study contributes
452 significantly to the limited evidence base in this area. We demonstrated that there was no
453 greater frequency of detection of SARS-CoV-2 from the environment of patients undergoing
454 AGPs compared to those on room air or oxygen. This suggests that the risk of aerosol
455 transmission may be equally significant in all areas where COVID-19 patients are cared for and

456 appropriate respiratory precautions should be recommended. This important evidence can
457 provide data to support infection prevention and control guidance in health care settings and
458 inform risk assessments and the use of AGPs in all settings.

459

460 **Implications of all available evidence**

461 SARS CoV-2 virus has been identified in the air in a range of healthcare settings where COVID-19
462 patients are managed. Our findings in combination with those reported by Winslow et al
463 suggest that AGPs do not present a uniformly increased transmission risk. Increased
464 understanding of the natural history of COVID-19 and transmission characteristics of SARS-CoV-
465 2, promote a move from the binary categories of AGP vs non-AGP for respiratory protection,
466 towards a risk assessment based primarily on the Patient and Place, as opposed to just the
467 procedure.

468 Appendix 1: Details of positive samples

469

470 Positive samples - procedure, ventilation and Ct values

Ventilation: Negative pressure (ets. 12 ACH), Neutral or standard ward ventilation (est 6 ACH), ITU and theatre (est. 10 ACH)	Procedure: narrower categories	PCR result	N gene	S gene	ORF1
Negative	High flow	Positive	Negative	20.87	Negative
Negative	CPAP	Positive	32.16	Negative	38.35
Negative	CPAP	Positive	26.48	35.34	20.05
Neutral	Room air	Positive	Negative	38.76	25.37
Neutral	Room air	Positive	37.96	Negative	38.16
ITU	CPAP	Positive	Negative	Negative	37.65
Negative	Nasal cannulae	Positive	34.83	Negative	Negative
Negative	Room air	Positive	34.43	38.45	32.14
Negative	CPAP	Positive	38.46	Negative	Negative
Neutral	rebreath mask	Positive	28.53	Negative	Negative
Neutral	Room air	Positive	33.17	Negative	Negative
Neutral	Nasal cannulae	Positive	33.03	Negative	Negative
Neutral	Room air	Positive	34.05	negative	34.16
Neutral	Venturi mask	Positive	32.25	Negative	34.71
Neutral	Nasal cannulae	Positive	36.78	Negative	36.13
Neutral	Nasal cannulae	Positive	32.32	Negative	Negative
Neutral	NK	Positive	34.7	Negative	35.91
Negative	CPAP	Positive	Negative	Negative	37.51
Negative	CPAP	Positive	Negative	Negative	22.79
Negative	Venturi mask	Positive	35.31	Negative	Negative
Neutral	NK	Positive	32.52	Negative	33.04
Negative	Nasal cannulae	Positive	30.94	23.96	33.57
Negative	CPAP	Positive	Negative	Negative	33.4
Theatre	Endoscopy	Positive	Negative	32.97	19.39
Negative	Nasal cannulae	Positive	negative	27.7	Negative
Negative	Intubation	Positive	28.66	Negative	28.88
Negative	CPAP	Positive	28.9	Negative	Negative
Negative	Venturi mask	Positive	24.89	32.5	22.17
NK	Nasal cannulae	Positive	Negative	Negative	33.41
Neutral	Room air	Positive	Negative	20.47	Negative
Neutral	Room air	Positive	38.57	Negative	Negative
Neutral	Room air	Positive	33.47	Negative	36.14
Negative	CPAP	Positive	34.65	Negative	Negative
Negative	NK	Positive	35.73	Negative	Negative
NK	Venturi mask	Positive	35.18	Negative	Negative
Negative	CPAP	Positive	37.65	negative	negative
Negative	Venturi mask	Positive	38.41	Negative	36.17
Neutral	Room air	Positive	35.05	Negative	35.45
Negative	Room air	Positive	35.24	negative	negative
Negative	High flow	Positive	36.52	negative	negative
Negative	High flow	Positive	36.5	negative	negative
Neutral	Room air	Positive	32.53	negative	negative
Neutral	Room air	Positive	Negative	Negative	36.46
Theatre	Bronchoscopy	Positive	negative	negative	38.41
Theatre	Bronchoscopy	Positive	negative	negative	37.73
Negative	Room air	Positive	34.21	negative	negative
Negative	Room air	Positive	21.52	Negative	39.57
Negative	Room air	Positive	negative	negative	34
Negative	Venturi mask	Positive	35.29	Negative	35.78
Neutral	Venturi mask	Positive	31.07	Negative	35.54
Negative	CPAP	Positive	30.43	Negative	35.48
Negative	Venturi mask	Positive	36.01	Negative	36.4
Neutral	Nasal cannulae	Positive	32.41	Negative	34.4
Negative	Venturi mask	Positive	32.96	Negative	Negative

471

472 NK Not known CPAP Continuous positive airway pressure

473

474 **Details of samples from other areas**

Ventilation: Negative pressure (est. 12 ACH), Neutral or standard ward ventilation (est. 6 ACH), ITU and theatre (est. 10 ACH)	Setting	Area directly occupied or used by SARS CoV-2 infected patients	PCR result	N gene	S gene	ORF1
ITU	Intubated patient	Yes	Positive	34.07	Negative	34.6
Neutral	Bathroom	Yes	Negative	Negative	Negative	Negative
Neutral	Bathroom	Yes	Positive	Negative	Negative	33.39
Neutral	Bathroom	Yes	Positive	34.89	Negative	Negative
Neutral	Bathroom	Yes	Negative	Negative	Negative	Negative
Negative	Nurses station	Yes	Negative	Negative	Negative	Negative
Negative	Nurses station	Yes	Negative	Negative	Negative	Negative
Negative	Near air vent	No	Negative	Negative	Negative	Negative
Negative	Nurses station	No	Positive	23.72	22.4	33.57
Negative	Centre of bay	No	Negative	Negative	Negative	Negative
Negative	Centre of bay	No	Negative	Negative	Negative	Negative
Negative	Nurses station	Yes	Negative	Negative	Negative	Negative
Negative	Nurses station	Yes	Negative	Negative	Negative	Negative
Negative	Nurses station	Yes	Negative	Negative	Negative	Negative
Negative	Nurses station	No	Negative	Negative	Negative	Negative
Negative	Nurses station	No	Positive	35.19	negative	negative

475

476

477 Appendix 2: Review of previous air sampling studies

478 Summary of previous air sampling studies in healthcare settings which included details of

	Number of samples, individuals (if applicable) and results of PCR and culture (if applicable)						AGPs and PCR	
Country	No. samples	No. patients	Air samples PCR positive/suspect	Proportion patients with ≥ 1 positive sample	Culture attempted (Y/N)	Evidence of viable virus described	Description of AGPs	Proportion PCR positive (AGPs)
UK (refs)	4	4	2/4	NK	Y	N	Tracheostomy (3), HFNO (1)	2 (4)
USA	15	15	0/15	0(15)	N	N	BiPAP (2), HFNO (3)	0(5)
Israel	4	NK	1/4	n/a	N	N	>1 patient on high flow	1(1)
S Korea	6	3	0/6	0(3)	N	N	HFNO (1)	0(1)
Hong Kong	6	6	0/6	0(6)	N	N	HFNO (1)	0(1)
China	12	12	1/12	1(12)	N	N	intubation	1(1)
UK	90	30	14/90	9 (30)	Y	N	HFNO (30), CPAP (30)	9(60)

479 sampling around aerosol generating procedures (AGPs)

480 PCR polymerase chain reaction, NK not known, n/a not applicable, HFNO high flow nasal

481 oxygen, CPAP continuous, AGP Aerosol generating procedure

482

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

483 **Summary of air sampling conducted** 1) around specified numbers of SARS-CoV-2 infected patients, 2)
 484 around unspecified numbers of infected patients and 3) in areas not occupied by COVID-19 patients
 485 from studies where infected patients were also sampled

			Number of samples, individuals (if applicable) and results of PCR and culture (if applicable)								
			Country	No. samples	No. patients	Proportion air samples PCR positive/suspect (all)	Proportion patients with ≥1 positive sample	Culture attempted (Y/N)	Evidence of viable virus described		
Sampling around specified number of COVID-19 infected patients	Hospital or clinic	Ong 2020	Singapore	6	3	0 (6)	0 (3)	N	N		
		Semelka 2021	USA	78	26		0 (26)	N	N		
		Ong 2021	Singapore	12	19	6 (12)	NK	Y	N		
		Wei 2020	China	34	9	0 (34)	0/9	N	N		
		Binder 2020	USA	195	20	3 (195)	3 (20)	Y	N		
		Guo 2020	China	48	39	15 (48)	NK	N	N		
		Lednický 2020	USA	4	2	4 (4)	NK	Y	Y		
		Faridi 2020	Iran	10	44	0 (10)	NK (0)	N	N		
		Dumont-Leblond	Canada	100	22	11 (100)	6 (22)	Y	N		
		Dubey 2021	India	24	12	17 (24)	12 (12) at 1m, 5	N	N		
		Chia 2020	Singapore	22 pooled into 4	3	2 (4)	2 (3)	N	N		
		Bokharaei-Salim	Iran	14	16	0 (14)	NK	N	N		
		Baboli 2021	Iran	29	25	4 (29)	NK	N	N		
		Santarpia 2020	USA	19	11	11 (19)	8 (11)	Y	Y		
		Razzini 2020	Italy	2	3	2 (2)	NK	N	N		
		Li 2020	China	14	9	2 (14)	1 (9)	N	N		
		Lei 2020	China	36	20	0 (36)	NK	N	N		
		Jin 2021	China	1	1	1 (1)	1 (1)	N	N		
		Quarantine facility or hotel	Ong 2021	Singapore	9	90	1 (9)	NK	Y	N	
	Ben-Shmuel 2021		Israel	1	1	1 (1)	1 (1)	N	N		
Sampling around unspecified number of COVID-19 patients	Hospital/clinic	Zhou 2020	UK	22	n/a	11 (22)	n/a	Y	N		
		Yuan 2020	China	32	n/a	0 (32)	NK	N	N		
		Lednický 2020	USA	2	NK	1 (2)	n/a	Y	Y		
		Li 2020	China	36	NK	0 (36)	n/a	N	N		
		Masoumbégi 2020	Iran	30	NK	0 (30)	NK	N	N		
		Kenarkoohi 2020	Iran	11	NK	2 (11)	NK	N	N		
		Hernandez 2021	Mexico	10	n/a	3 (10)	NK	N	N		
		Yuan 2020	China	11	n/a	8 (11)	NK	N	N		
		Ang 2021	Singapore	27	NK (wards full)	13 (27)	NK	Y	N		
		Barbieri 2021	Italy	6	NK	3 (6)	NK	N	N		
		Dubey 2021	India	6	NK	5 (6)	NK	N	N		
		Hemati 2021	Iran	35	NK	5 (35)	NK	N	N		
		Grimalt 2021	Spain	11	NK	11 (11)	NK	N	N		
		Sampling in areas not directly occupied by infected individuals	Hospital/clinic or quarantine facility	Ong 2020	Singapore	4	n/a	0 (4)			
				Zhou 2020	UK	5	n/a	1 (5)			
Yuan 2020	China			58	n/a	0 (58)					
Li 2020	China			99	n/a	0 (99)					
Masoumbégi 2020	Iran			1	n/a	0 (1)					
Guo 2020	China			66	n/a	1 (66)					
Kenarkoohi 2020	Iran			3	n/a	0 (3)					
Lane 2021	USA			528	n/a	0 (528)					
Tan 2020	China			17	n/a	0 (17)					
Ben-Shmuel 2021	Israel			1	n/a	0 (1)					
Hemati 2021	Iran			10	n/a	1 (10)					
Grimalt 2021	Spain			36	n/a	21 (36)					
Baboli 2021	Iran			22	n/a	2 (22)					
Dubey 2021	India			12	n/a	0 (12)					
Yuan 2020	China			24	n/a	14 (24)					
Santarpia 2020	USA			16	n/a	11 (16)					
Razzini 2020	Italy			3	n/a	0 (3)					
Jin 2020	China			1	n/a	0 (1)					
Lei 2020	China	99	n/a	0 (99)							